Temasek launches up to US$25m selldown in Shanghai Pharma: IFR
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[HONG KONG] Singapore state investor Temasek Holdings on Tuesday launched a selldown of up to US$25 million in Shanghai Pharmaceuticals, IFR reported, citing a term sheet of the transaction.
Temasek is offering 8 million shares of Shanghai Pharmaceuticals in an indicative range of HK$23.55 to HK$24.30 each, equivalent to a discount of up to 3 per cent to Tuesday's close, added IFR, a Thomson Reuters publication.
Goldman Sachs was hired as sole bookrunner of the selldown, the terms showed.
REUTERS
Share with us your feedback on BT's products and services
TRENDING NOW
Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS
Higher costs, lower returns: Why are Singaporeans still betting on real estate?
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
Loyang Valley sold for S$880 million to SingHaiyi-led consortium
